Since the lesion in the left lung was large enough to be removed surgically, upper lobectomy was performed.
Figure 1: Computed tomographic image of cavitary lesions in right and left lung.
Figure 2: Image of positron emission tomography of hypermetabolic lesions in right and left lung.
The histopathological examination of the specimen suggested a lesion consistent with ETT metastasis, and the presence of aspergilloma forms in the cavitary tumor was reported. The patient was uneventfully discharged. After one month, the patient was operated for a lesion located in right lung, and lower lobectomy was performed to the right lung due to the central localization of the lesion. The histopathological result was also reported as ETT metastasis. No malignancy was observed in the excised lymph nodes. The patient was discharged in the postoperative third day.
In the immunohistochemical examination, these tumors are positive for pan-cytokeratin, epithelial membrane antigen, E-cadherin and p63. They can be confused with squamous-cell carcinomas due to the epithelioid histological appearance and expression of p63 and cytokeratin.[3] We compared the metastasectomy materials of our patient with the hysterectomy material applied six years before and confirmed the diagnosis.
The literature on primary pulmonary occurrence and lung metastasis of ETT is limited. Although it is most commonly localized in the uterine, in a study with 14 cases by Shih and Kurman,[4] an ETT was located in the small intestine and lung in two cases without uterine diseases. Only two of 12 patients had lung and bone metastases. In another study with 78 cases, five of 11 patients with a uterine ETT and 10 of 20 patients without a uterine ETT had an ETT in the lungs, and the authors concluded that the lungs were the second most common localization site of ETTs.[3] In another study of nine cases, six patients had lung metastasis and only two metastasectomies were performed.[5] When the literature is reviewed, it is seen that most of the patients with lung metastasis have advanced disease and are not suitable for metastasectomy.[3-5] In our patient, positron emission tomography-computed tomography revealed no metastatic lesion or recurrence other than lung metastases. We came to the conclusion that the primary disease is under control, thus we decided surgery for the lung lesions.
The treatment decision for epithelioid trophoblastic tumors depends on the risk factors and prevalence of the disease. Treatment for diseases limited to uterus is hysterectomy.[6] After p rimary tumor resection, metastasectomy can be applied to eligible metastatic patients. Although epithelioid trophoblastic tumors are more resistant to chemotherapy unlike other trophoblastic tumors, chemotherapy can be combined with complete surgery.[6] It is well-known that successful resection of metastatic lung lesions increases survival.[7] Also, it has been suggested t hat parenchymal-sparing resection in metastasectomy is required for the surgery of future metastases.[7,8] Our case received anatomic resection due to size and central location of both tumors, the presence of aspergilloma and concerns about obtaining tumor-free margins. In this surgical result, lymph node metastasis was not detected and the patient was considered as tumor-free. Chemotherapy was not applied to the patient postoperatively. The patient is still under follow-up without any problems for 12 months. To our knowledge, this is the first case which underwent bilateral metastasectomy for epithelioid trophoblastic tumor.
Declaration of conflicting interests
The authors declared no conflicts of interest with respect to
the authorship and/or publication of this article.
Funding
The authors received no financial support for the research
and/or authorship of this article.
1) Davis MR, Howitt BE, Quade BJ, Crum CP, Horowitz NS,
Goldstein DP, et al. Epithelioid trophoblastic tumor: A single
institution case series at the New England Trophoblastic
Disease Center. Gynecol Oncol 2015;137:456-61.
2) Keser SH, Kokten SC, Cakir C, Sensu S, Buyukbayrak EE,
Karadayi N. Epithelioid trophoblastic tumor. Taiwan J Obstet
Gynecol 2015;54:621-4.
3) Zhang X, Lü W, Lü B. Epithelioid trophoblastic tumor: an
outcome-based literature review of 78 reported cases. Int J
Gynecol Cancer 2013;23:1334-8.
4) Shih IM, Kurman RJ. Epithelioid trophoblastic tumor: a
neoplasm distinct from choriocarcinoma and placental site
trophoblastic tumor simulating carcinoma. Am J Surg Pathol
1998;22:1393-403.
5) Shen X, Xiang Y, Guo L, Ren T, Feng F, Wan X, et al.
Analysis of clinicopathologic prognostic factors in 9 patients
with epithelioid trophoblastic tumor. Int J Gynecol Cancer
2011;21:1124-30.
6) Horowitz NS, Goldstein DP, Berkowitz RS. Placental site
trophoblastic tumors and epithelioid trophoblastic tumors:
Biology, natural history, and treatment modalities. Gynecol
Oncol 2017;144:208-14.